Tvardi Therapeutics (TVRD) Institutional Ownership $38.24 -0.50 (-1.29%) As of 09/19/2025 04:00 PM Eastern Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Tvardi Therapeutics (NASDAQ:TVRD)CurrentInstitutional OwnershipPercentage44.66%Number ofInstitutional Buyers(last 12 months)9TotalInstitutional Inflows(last 12 months)$24.39MNumber ofInstitutional Sellers(last 12 months)0 Get TVRD Insider Trade Alerts Want to know when executives and insiders are buying or selling Tvardi Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data TVRD Institutional Buying and Selling by Quarter Tvardi Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/16/2025 Headlands Technologies LLC3,431$80K0.0%N/A0.037% 8/15/2025 Bank of America Corp DE17,085$399K0.0%N/A0.183% 8/15/2025 683 Capital Management LLC176,030$4.11M0.3%N/A1.881% 8/14/2025 MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.1,863$43K0.0%N/A0.020% 8/14/2025 Slate Path Capital LP704,118$16.43M0.3%N/A7.523% 8/13/2025 Marshall Wace LLP24,980$583K0.0%N/A0.267% 8/13/2025 New York State Common Retirement Fund4,000$92K0.0%N/A0.043% 8/12/2025 JPMorgan Chase & Co.1,668$39K0.0%N/A0.018% 8/8/2025 Geode Capital Management LLC112,138$2.62M0.0%N/A1.198% (Data available from 1/1/2016 forward) TVRD Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of TVRD shares? During the previous two years, 9 institutional investors and hedge funds held shares of Tvardi Therapeutics. The most heavily invested institutionals were Slate Path Capital LP ($16.43M), 683 Capital Management LLC ($4.11M), Geode Capital Management LLC ($2.62M), Marshall Wace LLP ($583K), Bank of America Corp DE ($399K), New York State Common Retirement Fund ($92K), and Headlands Technologies LLC ($80K).Learn more on Tvardi Therapeutics' institutional investors. What percentage of Tvardi Therapeutics' stock is owned by institutional investors? 44.66% of Tvardi Therapeutics' stock is owned by institutional investors. Learn more on TVRD's institutional investor holdings. Which institutional investors have been buying Tvardi Therapeutics' stock? Of the 9 institutional investors that purchased Tvardi Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Slate Path Capital LP ($704.12K), 683 Capital Management LLC ($176.03K), Geode Capital Management LLC ($112.14K), Marshall Wace LLP ($24.98K), Bank of America Corp DE ($17.09K), New York State Common Retirement Fund ($4K), and Headlands Technologies LLC ($3.43K). How much institutional buying is happening at Tvardi Therapeutics? Institutional investors have bought a total of 1,045,313 shares in the last 24 months. This purchase volume represents approximately $24.39M in transactions. Related Companies Stoke Therapeutics Major Shareholders 89BIO Major Shareholders Xeris Biopharma Major Shareholders Evotec Major Shareholders Precigen Major Shareholders Collegium Pharmaceutical Major Shareholders Zymeworks Major Shareholders Intellia Therapeutics Major Shareholders Arcus Biosciences Major Shareholders Tourmaline Bio Major Shareholders This page (NASDAQ:TVRD) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tvardi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tvardi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TVRD Stock Alerts